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Chapter 19. In vitro studies of phenol coupling enzymes involved
in vancomycin biosynthesis
Abstract
Oxidative phenol cross-linking reactions play a key role in the biosynthesis of glycopeptide antibiotics
such as vancomycin. The vancomycin aglycone contains three cross-links between aromatic amino acid
side-chains, which stabilize the folded backbone conformation required for binding to the target
D-Ala-D-Ala dipeptide. At least the first cross-link is introduced into a peptide precursor whilst it is still
bound as a thioester to a peptide carrier protein (PCP) domain (also called a thiolation domain) within
the nonribosomal peptide synthetase. We described here methods for the solid-phase synthesis of
peptides and their coupling to PCP domains, which may be useful for in vitro studies of cross-linking
and related tailoring reactions during nonribosomal glycopeptide antibiotic biosynthesis.
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Abstract 
Oxidative phenol cross-linking reactions play a key role in the biosynthesis of glycopeptide 
antibiotics such as vancomycin. The vancomycin aglycone contains three cross-links between 
aromatic amino acid side chains, which stabilize the folded backbone conformation required 
for binding to the target D-Ala-D-Ala dipeptide. At least the first cross-link is introduced into 
a peptide precursor whilst it is still bound as a thioester to a peptide carrier protein (PCP) 
domain (also called a thiolation domain) within the non-ribosomal peptide synthetase. We 
described here methods for the solid-phase synthesis of peptides and their coupling to PCP 
domains, which may be useful for in vitro studies of cross-linking and related tailoring 
reactions during non-ribosomal glycopeptide antibiotic biosynthesis. 
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Introduction 
One of the strategies used in Nature to create conformationally constrained peptides involves 
oxidative cross-linking of aromatic amino acid side chains. Examples are found in the 
glycopeptide antibiotics, such as vancomycin and teicoplanin (Figure-1), which contain 
biaryl ether (C-O-C) as well as direct biaryl (C-C) cross-links (Hubbard and Walsh, 2003). 
These are essential for the creation within the glycopeptide scaffold of a binding site for the 
dipeptide D-Ala-D-Ala found in intermediates of bacterial peptidoglycan biosynthesis. Such 
aromatic C-O-C and C-C cross-links, however, occur more widely in Nature, for example, in 
the closely related bacterial metabolites complestatin (Seto et al., 1989), kistamicin (Naruse 
et al., 1993) and chloropeptin (Matsuzaki et al., 1994), as well as in peptidic natural products 
such K-13 (Yasuzawa et al., 1987), bouvardin (Jolad et al., 1977) and the related plant 
metabolites RA-I-XVI (Hitotsuyanagi et al., 2004), OF4949 (Sano et al., 1986), the 
arylomycins (Holtzel et al., 2002), the biphenomycins (Uchida et al., 1985), the TMC-95 
family (Kohno et al., 2000), and RP-664536 (Helynck et al., 1998). 
 
Figure-1. 
 
 Oxidative phenol coupling reactions also play a key role in plant alkaloid 
biosynthesis, especially benzylisoquinoline alkaloids such as morphine (Ziegler and Facchini, 
2008). The first report of the purification and cloning of a cytochrome P450 enzyme 
catalyzing a regio and stereospecific oxidative C-O-C phenol coupling was of berbamunine 
synthase from Berberis stolonifera (Kraus and Kutchan, 1995). A related P450 catalyzing a 
C-C coupling was cloned recently from Coptis japonica, which converts (S)-reticuline into 
(S)-corytuberine (Ikezawa et al., 2008). These plant enzymes, however, appear to be 
membrane bound proteins. In contrast, several soluble microbial P450 enzymes have also 
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been cloned and studied recently that catalyze phenol (and related) coupling reactions. These 
include a flaviolin oxidase (Zhao et al., 2005), a tetrahydroxynaphthalene oxidase (Funa et 
al., 2005), an indole-indole coupling enzyme (StaP) involved in staurosporine biosynthesis 
(Howard-Jones and Walsh, 2007; Makino et al., 2007), and last but not least, the enzyme 
OxyB, which catalyzes the first cross-linking step in the biosynthesis of vancomycin and 
related glycopeptides (Woithe et al., 2007; Zerbe et al., 2004). 
 The three oxidative cross-linking reactions during vancomycin biosynthesis are 
catalyzed in a defined order by three closely related cytochrome P450s, called OxyA, OxyB 
and OxyC (following the order of their genes in the bacterial chromosome). The first 
coupling reaction occurs between the phenol rings in residues-4 and -6 (the C-O-D ring), 
catalyzed by OxyB, the second aryl-ether bridge is formed between side chains of residues-2 
and -4 (D-O-E ring) by OxyA, and the last biaryl coupling between the aromatic side chains 
of residues-5 and -7 is carried out by OxyC (AB ring, Figure-1) (Bischoff et al., 2001a; 
Bischoff et al., 2001b; Sussmuth et al., 1999). The crystal structures of OxyB (CYP165B1) 
and OxyC (CYP165C1) from the vancomycin producer A. orientalis have been reported in 
substrate free forms (Pylypenko et al., 2003; Zerbe et al., 2002), confirming that these 
proteins indeed contain a fold and heme environment typical of P450 enzymes. 
 
Figure-2.  
  
 The heptapeptide backbones of glycopeptides are constructed by the actions of large 
non-ribosomal peptide synthetase (NRPS) multidomain proteins (NRPS-1, -2 and -3, Figure-
2). According to the so-called thiotemplate mechanism of assembly, peptidic intermediates 
remain bound as C-terminal thioesters to pantetheinyl groups attached to peptide carrier 
protein (PCP) domains (also called thiolation, or T domains) within the NRPS assembly line 
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(Grünewald and Marahiel, 2006). Each module in the NRPS is responsible for the 
incorporation of one amino acid, and contains at least a PCP domain and an amino acid 
activating (A) domain, usually also a condensation (C) domain, and sometimes also an 
epimerization (E) domain amongst others. Seven modules are required to assemble 
glycopeptide heptapeptide backbones, which according to bioinformatic analyses are 
distributed between three (in a 3:3:1 distribution) or four (in a 2:1:3:1 distribution) NRPS 
subunits for the vancomycin-like and teicoplanin/complestatin-type glycopeptides, 
respectively (Donadio et al., 2005). Fused to module 7 is a domain (X) of unknown function 
and a thioesterase (TE) domain. Only recently has it become clear that whilst being shuffled 
along and remaining covalently anchored to the NRPS assembly line, the peptide 
intermediates may also be transformed by other enzymes acting in trans. This has been 
demonstrated in vitro for OxyB in vancomycin-like glycopeptides (Woithe et al., 2007; Zerbe 
et al., 2004), and may well also be true for the other cross-linking enzymes, and the 
halogenases which introduce Cl atoms into aromatic residues during glycopeptide 
biosynthesis. 
 For in vitro studies of glycopeptide cross-linking and halogenase enzymes access is 
required to suitable substrates, namely, peptides linked as thioesters to fragments of the 
NRPS, in particular, isolated recombinant PCP domains (Figure-2). The production of such 
peptide-PCP conjugates is often not straightforward, due to the stereochemical and chemical 
lability of these molecules. The approach described here involves first the solid-phase 
synthesis of a suitable peptide (Figure-3).  
 
Figure-3.  
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The required synthetic peptides typically contain hydroxyphenylglycine (Hpg) and ß-
hydroxytyrosine (Bht) derivatives, which are often rapidly epimerized and/or degraded upon 
treatment with acids and bases. Thus, the peptides cannot be synthesized efficiently using 
standard Fmoc- and Boc-methods of solid-phase peptide synthesis. Next, the peptide should 
be activated at the C-terminus, first as an S-phenyl and then an S-CoA thioester. With the 
peptide-SCoA thioester, the broad specificity pantetheinyl transferase Sfp from B. subtilis 
(Quadri et al., 1998) can be used to transfer the entire peptide-pantetheinyl portion to the 
active site Ser residue of a recombinant apo-PCP domain. Finally, a suitable fragment of the 
NRPS comprising an intact PCP domain must be produced in the apo-form. Although 
powerful general methods exist for producing large amounts of protein in the cytoplasm of E. 
coli, the expression protocol used and the choice of N- and C-termini for the PCP domain can 
have a major influence on its folding and solubility in aqueous buffers. Below, we expand on 
one approach for synthesizing such molecules, which has been validated recently in the 
production of a variety of peptide-PCP conjugates for in vitro studies of glycopeptide 
antibiotic cross-linking enzymes (Geib et al., 2008; Woithe et al., 2008; Woithe et al., 2007). 
 
1. Peptide Synthesis 
As a typical example, we focus here on the model hexapeptide 1 (Figure-4) and its use for in 
vitro assays with OxyB.  The methods described here for the production of 1 and its PCP-
bound form (1-S-PCP) can, however, be readily adapted for the production of a variety of 
other related peptide-PCP conjugates. In the interests of ease of synthesis, ß-hydroxytyrosine 
is incorporated only at position-6 of this hexapeptide, although the biosynthetic logic (Figure-
2) dictates that ß-hydroxytyrosine, or perhaps m-chloro-ß-hydroxytyrosine, should be present 
at both positions-2 and -6. In earlier studies, model substrates containing tyrosine at both 
positions-2 and -6 were produced and used for in vitro studies of OxyB (Geib et al., 2008; 
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Woithe et al., 2008; Woithe et al., 2007; Zerbe et al., 2004). Also for synthetic convenience, 
the peptide 1 has an N-methylated D-Leu at the N-terminus. Experience has shown that an 
unprotected N-terminal N-methylamino group is compatible with thioester formation at the 
C-terminus, under the conditions used. Note, however, that N-methylation occurs late in the 
vancomycin biosynthetic pathway, after aglycone formation is complete (O'Brien et al., 
2000), and that the N-methyl group does not influence to any significant extent the cross-
linking reaction catalyzed by OxyB (Woithe et al., 2008; Woithe et al., 2007). 
 
Figure-4. 
 
If peptides are required with an unmethylated N-terminus, then the N-terminal primary amino 
group should be protected such as with a t-butoxycarbonyl (Boc) group during thioester 
formation at the C-terminus (Figure-3). The Boc group can be removed from the peptide after 
formation of an S-phenyl thioester by brief treatment with TFA (Woithe et al., 2007). 
 The free linear peptide 1-OH is first prepared by solid-phase peptide synthesis. The 
assembly of 1-OH can be achieved efficiently using N-allyloxycarbonyl (Alloc) protected 
amino acids by solid-phase synthesis on chlorotrityl chloride (CT) resin (Freund and 
Robinson, 1999; Li and Robinson, 2005). Where necessary, N-Alloc and side chain O-allyl 
protecting groups can be removed using Pd-catalysis under neutral conditions. Here, an effort 
has been made to avoid as far as possible side chain protecting groups, since some (e.g. 
benzyl groups) can be very difficult to remove cleanly from such labile peptides. The side 
chain protection of Asn is also avoided, but then exposure to the normal activating reagents 
(e.g. HBTU/HOBt) can lead to side reactions in the Asn side chain amide, so this and the 
amino acids subsequently added to the peptide on the resin are coupled as pentafluorophenyl 
(Pfp) esters. When assembly is complete, only minimal exposure of the resin to acid is 
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needed (0.6% TFA in CH2Cl2) to release the fully assembled peptide (1-OH) into solution, 
which can be purified and used for further studies. Hence, the protected amino acids required 
for the synthesis of 1-OH are those shown in Figure-4. Below the synthesis of peptide 1-OH 
is described in detail. 
 All synthetic transformations must be performed in a well-ventilated fume hood 
designed for organic synthesis use, and carried out only by suitably trained personnel. 
Avoid direct contact with all chemicals used. 
 
Step-1. Synthesis of amino acid 2.  The protected amino acid (Bht) 2 can be prepared using 
Evans aldol chemistry, as shown in Figure-5 (Evans and Weber, 1986; Evans and Weber, 
1987). The allyl group was chosen for protection of the phenol, since it can be removed under 
neutral conditions with Pd-catalysis during cleavage of the N-Alloc group. 
 
Figure-5.  
 
 Compound 9 was prepared as follows. Stannous triflate (5.0 g, 12 mmol) and dry THF 
(70 ml) were cooled to -78oC under Ar. N-Ethylpiperidine (2.5 ml, 18 mmol) was added 
slowly, and stirred for 5 min. The oxazolidinone 7 (2.76 g, 10 mmol) was added in dry THF 
at -78 oC, and the mixture was stirred for 1.5 h. The aldehyde 8 was then added, and the 
mixture was stirred at -78oC for 2 h. The reaction was quenched by addition of sodium 
phosphate buffer pH 7, filtered through celite, and the aqueous phase extracted with CH2Cl2. 
The organic extract was washed with 1N aqueous sodium bisulphate, dried over anhydrous 
sodium sulfate, and concentrated in vacuo. The product was purified by flash 
chromatography on silica gel (n-hexane:EtOAc, 2:1, Rf 0.3) to give 9 as a white foam (3.39 g, 
77%). 1H-NMR (300 MHz, CDCl3) δ 2.95 (1H, dd), 3.27 (1H, dd), 4.35 (2H, m), 4.57 (2H, 
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d), 4.78 (1H, m), 5.06 (1H, d), 5.30 (1H, d), 5.45 (1H, d), 6.05 (1H, m), 6.38 (1H, d), 6.95 
(2H, d) 7.20 (2H, d), 7.35 (2H, m), 7.40 (3H, m), 7.75 (1H, s). 
 To the aldol adduct 9 (3.39 g, 7.74 mmol) in anhydrous MeOH (20 ml) and CH2Cl2 
(20 ml) at 0oC was added a suspension formed by the addition of MeMgBr (2.66 ml, 8.51 
mmol) in dry diethylether (3.2 M) to anhydrous MeOH (10 ml) (Evans and Weber, 1987). 
After stirring for 10 min, the reaction was quenched by addition of 1N aqueous sodium 
bisulfate. The volatile solvent was removed in vacuo, and the aqueous phase was extracted 
three times with CH2Cl2. The combined organic phase was then dried over anhydrous sodium 
sulfate and evaporated in vacuo. The product was purified by flash chromatography on silica 
gel (n-hexane:EtOAc, 2:1, Rf 0.3) to give 10 as a light yellow oil (1.72 g, 76%). 1H-NMR 
(300 MHz, CDCl3) δ 3.98 (3H, s), 4.60 (1H, d), 4.67 (2H, m), 5.40 (1H, m), 5.52 (1H, m), 
6.01 (1H, d), 6.15 (1H, m), 7.06 (2H, d), 7.42 (2H, d), 7.72 (1H, br. s). 
 To the methyl ester 10 (1.72 g, 5.87 mmol) in dry CH2Cl2 (20 ml) was added Boc2O 
(1.41 g, 6.45 mmol) and 4-(dimethylamino)-pyridine (36 mg, 0.29 mmol). The mixture was 
stirred at room temperature for 1 h. After cooling to 0oC, a 30% solution of H2O2 (5 ml) and 
formic acid (5 ml) were added and the mixture was stirred vigorously for 30 min. Then 1N 
aqueous sodium bisulphate was added, the organic layer was separated, and the aqueous 
phase was extracted 3 times with CH2Cl2. The organic phases were combined, dried over 
anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash 
chromatography on silica gel (n-hexane:EtOAc, 2:1, Rf 0.5) to give 11 as a colorless oil (1.12 
g, 51%). 1H-NMR (300 MHz, CDCl3) δ 1.62 (9H, s), 4.00 (3H, s), 4.69 (2H, m), 4.77 (1H, d), 
5.42 (1H, m), 5.43 (1H, d), 5.55 (1H, m), 6.18 (1H, m), 7.10 (2H, d), 7.42 (2H, d). 
 To compound 11 (1.12g, 2.98 mmol) dissolved in dioxane (20 ml) at room 
temperature was added a 2N aqueous LiOH solution (7.45 ml, 14.9 mmol) and the resulting 
mixture was stirred overnight. The reaction was quenched by addition of 1N aqueous sodium 
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bisulfate, and extracted 3 times with CH2Cl2. The combined organic extracts were dried over 
anhydrous sodium sulfate and concentrated in vacuo. The product was purified by flash 
chromatography on silica (CH2Cl2:MeOH:AcOH, 100:1:0.5) to give the product as a 
colorless oil (660 mg, 66%). 1H-NMR (300 MHz, DMSO) δ 1.30 (9H, s), 3.30 (OH), 4.18 
(1H, m), 4.55 (2H, d), 5.01 (1H, s), 5.25 (1H, m), 5.40 (1H, m), 6.03 (1H, m), 6.29 (1H, d), 
6.90 (2H, m), 7.27 (2H, d), 12.15 (1H, br. s). This material (560 mg, 1.67 mmol) was 
dissolved in 4N HCl in dry dioxane (5 ml). After stirring for 1h at room temperature, the 
solution was evaporated to dryness in vacuo to afford the amino acid hydrochloride salt. 
 In preparation for the formation of 2, allyloxycarbonyl-N-hydroxysuccinimide ester 
(Alloc-OSu) was prepared (Hayakawa et al., 1986). Thus, to allyloxycarbonyl chloride (170 
µl, 1.6 mmol) and N-hydroxysuccinimide (184 mg, 1.6 mmol) in dry THF (2 ml) was added 
dropwise over 5 min triethylamine (223 µl, 1.6 mmol). After stirring for 30 min at room 
temperature, the solution was filtered, and the clear filtrate was evaporated to dryness in 
vacuo to afford Alloc-OSu, which was used immediatley without further purification. 
 The amino acid-HCl salt from above (1.67 mmol) and sodium bicarbonate (335 mg, 
4.1 mmol) in a mixture of water (5 ml) and acetone (5 ml) was added to the freshly prepared 
Alloc-OSu, and the mixture was stirred at room temperature overnight. The volatiles were 
removed in vacuo, then the pH was adjusted to 2 with dil. HCl and the remaining aqueous 
solution was extracted with EtOAc. The organic extracts were dried over anhydrous sodium 
sulfate and evaporated to dryness in vacuo to afford 2 (320 mg, 60%) as a white solid. 1H-
NMR (300 MHz, DMSO) δ 3.30 (OH), 4.20 (1H, m), 4.38 (2H, m), 4.55 (2H, m), 4.70 (1H, 
d), 5.10-5.30 (3H, m), 5.40 (1H, d), 5.80 (1H, m), 6.05 (1H, m), 6.90 (2H, d), 6.95 (1H, s), 
7.30 (2H, d), 12.7 (1H, br. s). 
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Step-2. Synthesis of amino acid 3. To a stirred solution of D-4-hydroxyphenylglycine (3.34 g, 
20 mmol) and sodium bicarbonate (2.4 g, 14 mmol) in water/acetone (1:1, 80 ml) was added 
freshly prepared Alloc-OSu (3.98 g, 20 mmol) (see above) (Paquet, 1982). The mixture was 
stirred for 5 h. The pH was then adjusted to 2 with dil. HCl, and after removal of acetone in 
vacuo, the aqueous layer was extracted with EtOAc. The extracts were dried over anhydrous 
sodium sulfate, and evaporated to afford an oil, which was crystallized from ether/hexane to 
give a white solid (3.88 g, 77%). 1H-NMR (300 MHz, DMSO) δ 3.35 (OH), 4.50 (2H, d), 
5.00 (1H, d), 5.15 (1H, d), 5.30 (1H, d), 5.90 (1H, m), 6.73 (2H, d), 7.20 (2H, d), 7.85 (1H, 
d), 9.45 (1H, br. s). 
 
Step-3. Synthesis of amino acid 4. Alloc-Asn-OH was first prepared from Asn using the 
procedure described in step-2. The pentafluorophenyl (-OPfp) ester was then prepared as 
follows. To a stirred solution of Alloc-Asn-OH (1.3 g, 6 mmol) and pentafluorophenol (3.68 
g, 20 mmol) in dry dioxane (20 ml) at 0oC was added dicyclohexylcarbodiimide (1.51 g, 7.2 
mmol). The mixture was stirred at 0oC for 2 h and at room temperature for 3 h. The urea was 
then filtered off, solvent was removed in vacuo, the residue was triturated with n-hexane, and 
the resulting solid was recrystallized from n-hexane/EtOAc to give the product as a white 
solid (1.41 g, 61%), which is used directly without purification. 1H-NMR (300 MHz, DMSO) 
δ 2.45 (2H, m), 4.28 (1H, m), 4.43 (2H, d), 5.10 (1H, d), 5.23 (1H, d), 5.85 (1H, m), 6.85 
(1H, br. s), 7.30 (1H, br. s), 7.32 (1H, d). 
 
Step-4. Synthesis of amino acid 5. The amino acid 5 is prepared in five steps from D-tyrosine. 
First, acetyl chloride (5.6 ml, 72 mmol) was added dropwise to methanol (30 ml) and stirred 
at 0oC for 15 min, then  D-Tyr (4.73 g, 26 mmol) was added in portions and the mixture was 
refluxed for 3 h. The solvent was then evaporated in vacuo to give a white solid, which was 
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used without purification.  1H-NMR (300 MHz, D2O) δ 3.42 (2H, m), 4.07 (3H, s), 4.60 (1H, 
m), 7.10 (2H, d), 7.40 (2H, d). 
 Second, the D-Tyr-OMe.HCl salt prepared as above (4.47 g, 19 mmol) was dissolved 
in acetone/water (1:1, 40 ml) and sodium bicarbonate (4.0 g, 48 mmol) was added, followed 
by freshly prepared Alloc-OSu (3.98 g, 20 mmol, prepared as above). The mixture was 
stirred overnight at room temperature. The pH was then adjusted to 2-3 with dil HCl, the 
acetone was removed in vacuo, and the aqueous phase was extracted three times with EtOAc. 
The organic extracts were dried over anhydrous sodium sulfate and evaporated to dryness in 
vacuo, to give a colorless oil, which was used without purification (TLC, silica n-
hexane:EtOAc (1:1) showed a single component, Rf 0.75).  
 Third, the Alloc-D-Tyr-OMe (5.31 g, 19 mmol) was dissolved in dry DMF (30 ml) 
and potassium carbonate (5.32 g, 38 mmol), allyl bromide (2.5 ml, 24 mmol), and n-Bu4NBr 
(1.9 g, 5 mmol) were added. The mixture was stirred for 24 h at room temperature. Then 1N 
sodium bisulfate was added and the mixture was extracted three times with EtOAc. The 
organic extracts were washed with brine, dried over anhydrous sodium sulfate and evaporated 
to dryness in vacuo. The resulting oil (5.8 g, 96%) was used without purification (TLC, silica 
n-hexane:EtOAc (2:1) showed a single component, Rf 0.3). 1H-NMR (300 MHz, acetone) δ 
3.13 (1H, dd), 3.28 (1H, dd), 3.89 (3H, s), 4.63 (1H, m), 4.68 (2H, m), 4.75 (2H, m), 5.32 
(1H, m), 5.45 (1H, m), 5.48 (1H, m), 5.60 (1H, m), 6.08 (1H, m), 6.25 (1H, m), 6.62 (1H, 
br.d), 7.08 (2H, d), 7.39 (2H, d). 
 Fourth, the Alloc-D-Tyr(allyl)-OMe (5.8 g, 18 mmol) was dissolved in THF:water 
(1:1, 30 ml) and LiOH.H2O (1.01 g, 24 mmol) was added with stirring at 0oC overnight. The 
pH was then adjusted to 2-3 with dil HCl, the THF was removed in vacuo, and the aqueous 
phase was extracted three times with CH2Cl2. The organic extracts were dried over anhydrous 
sodium sulfate and evaporated to dryness in vacuo, to give a colorless oil (5.47 g, 99%).  1H- 
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NMR (300 MHz, DMSO) δ 2.90 (1H, m), 3.10 (1H, m), 3.40 (br. OH), 4.21 (1H, m), 4.55 
(2H, m), 4.67 (2H, m), 5.27 (1H, m), 5.35 (2H, m), 5.39 (1H, m), 5.50 (1H, m), 5.95 (1H, m), 
6.15 (1H, m), 6.97 (2H, d), 7.29 (2H, d), 7.60 (1H, d). 
 Fifth, the Alloc-D-Tyr(allyl)-OH (5.2 g, 17 mmol) and C6F5-OH (3.35 g, 18 mmol) in 
dry dioxane (20 ml) at 0oC was treated with dicyclohexylcarbodiimide (3.7 g, 18 mmol). 
After stirring 1 h at 0oC, and another 1 h at room temperature, the mixture was filtered, and 
the filtrate was concentrated in vacuo. The resulting oil was crystallized from n-hexane and 
diethyl ether to give the product 5 as a white solid (6.2 g, 76%). 1H NMR (300 MHz, CDCl3) 
δ 3.50 (2H, m), 4.82 (2H, m), 4.88 (2H, m), 5.21 (1H, m), 5.40 (1H, br. d), 5.50 (1H, d), 5.53 
(1H, m), 5.60 (1H, m), 5.68 (1H, m), 6.18 (1H, m), 6.33 (1H, m), 7.17 (2H, d), 7.41 (2H, d). 
 
Step-5. Synthesis of amino acid 6. To N-Methyl-D-leucine (184 mg, 1.27 mmol) in 
dioxane:water (1:1, 10ml) was added sodium bicarbonate (1.07 g, 12.7 mmol) and Alloc-
chloride (1.35 ml, 12.7 mmol) and the mixture was stirred overnight at room temperature. 
The volatiles were then removed in vacuo, and the aqueous phase (pH 8) was extracted with 
diethyl ether. The aqueous phase was then adjusted to pH 2-3 with dil. HCl and was again 
extracted with ether. The ether extract was dried over anhydrous sodium sulfate and 
evaporated to dryness in vacuo to give Alloc-N-methyl-D-Leu-OH (270 mg, 93%). This 
material was dissolved in dry dioxane (5 ml) and pentafluorophenol (217 mg, 1.18 mmol) 
was added followed by dicyclohexylcarbodiimide (243 mg, 1.18 mol) and the mixture was 
stirred at 0oC for 1 h then at room temperature for 2 h. The urea was removed by filtration 
and the filtrate was evaporated to dryness in vacuo, to afford the product as an oil, which was 
used without further purification. 1H-NMR (300 MHz, CDCl3) δ 0.90 (6H, m), 1.51-1.82 
(3H, m), 2.80 (3H, s), 2.90 (1H, m), 4.08 (2H, m), 5.20 (2H, m), 5.58 (1H, m). 
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Step-6. Peptide assembly  
Step-6A. Loading residue-6 on the resin. The amino acid 2 (320 mg, 1 mmol) was dissolved 
in a mixture of dry CH2Cl2 and dry DMF (19:1, 15 ml) and dry N-methylmorpholine (510 µl, 
4.7 mmol) was added. This mixture was added to freshly activated and dried CT-resin (1.2 g, 
1.56 mmol/g, Novabiochem) and stirred at room temperature overnight. Methanol (5 ml) was 
then added and the mixture was agitated for 10 min. The resin was then filtered and washed 
successively with DMF (4 x 25 ml), MeOH (4 x 25 ml) and CH2Cl2 (4 x 25 ml). The 
presence of amino acid on the resin was checked by treating a few resin beads with 
trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 (100 µl), and analysis by HPLC-MS. 
Step-6B. Deprotection. To this resin (600 mg) under Ar-atmosphere in the dark was added a 
solution of Pd(PPh3)4 (200 mg, 0.7 mmol) and PhSiH3 (1.3 ml, 10.6 mmol) in CH2Cl2 (15 
ml), and the mixture was agitated for 3 h. The resin was then filtered and washed 
successively with DMF (4 x 25 ml), CH2Cl2 (4 x 25 ml) and DMF (4 x 25 ml). A few resin 
beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 (100 µl), and 
analysis by HPLC-MS was performed to ensure that deprotection was complete. 
Step-6C. Coupling residue-5. To the resin was added 3 (251 mg, 1 mmol), 
diisopropylcarbodiimide (DIC) (126 mg, 1 mmol) and 1-hydroxybenzotriazole (HOBt) (306 
mg, 2 mmol) in dry DMF (10 ml) and the mixture was agitated overnight at room 
temperature. The resin was then filtered and washed with DMF (4 x 25 ml) and CH2Cl2 (4 x 
25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 
(100 µl), and analysis by HPLC-MS was performed to ensure that coupling was >95% 
complete. The Alloc group was then removed using the procedure in step-6B. 
Step-6D. Coupling residue-4. This step was carried out as described for step-6C. 
Step-6E. Coupling residue-3. For this step, the freshly prepared amino acid derivative 4 was 
used (see above). The compound 4 (382 mg, 1 mmol) and HOBt (306 mg, 2 mmol) in dry 
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DMF (10 ml) was added to the resin, and the mixture was agitated overnight at room 
temperature. The resin was then filtered and washed with DMF (4 x 25 ml) and CH2Cl2 (4 x 
25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 
(100 µl), and analysis by HPLC-MS was performed to check that coupling was >95% 
complete. At this stage it is necessary to use nBu3SnH instead of PhSiH3 as hydride donor in 
the deprotection step. Thus, under Ar-atmosphere in the dark a solution of Pd(PPh3)4 (140 
mg, 0.49 mmol) and nBu3SnH (2 ml, 7.43 mmol) in CH2Cl2 (15 ml) was added to the resin 
and the mixture was agitated for 3 h at room temperature. The resin was then filtered and 
washed successively with DMF (4 x 25 ml), CH2Cl2 (4 x 25 ml) and DMF (4 x 25 ml). A few 
resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 (100 µl), and 
analysis by HPLC-MS was performed to ensure that deprotection was complete. 
Step-6F. Coupling residue-2. For this step, the freshly prepared amino acid derivative 5 was 
used (see above). To the resin was added compound 5 (473 mg, 1 mmol) and HOBt (153 mg, 
1 mmol) in dry DMF (10 ml), and the mixture was agitated overnight at room temperature.  
The resin was then filtered and washed with DMF (4 x 25 ml) and CH2Cl2 (4 x 25 ml). A few 
resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 (100 µl), and 
analysis by HPLC-MS was performed to check that coupling was >95% complete. Removal 
of the N-Alloc and O-allyl groups was performed using the procedure described in step-6E, 
with nBu3SnH as hydride donor. Then, a few resin beads were treated with trifluoroacetic 
acid (TFA, 0.6%, v/v) in CH2Cl2 (100 µl), and analysis by HPLC-MS was performed to 
ensure that deprotection was complete. 
Step-6G. Coupling residue-1. For this step, the freshly prepared amino acid derivative 6 was 
used (see above). To the resin was added compound 6 (435 mg, 1.1 mmol) and HOBt (168 
mg, 1.1 mmol) in dry DMF (10 ml), and the mixture was agitated overnight at room 
temperature.  The resin was then filtered and washed with DMF (4 x 25 ml) and CH2Cl2 (4 x 
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25 ml). A few resin beads were treated with trifluoroacetic acid (TFA, 0.6%, v/v) in CH2Cl2 
(100 µl), and analysis by HPLC-MS was performed to ensure that coupling was >95% 
complete. Removal of the N-Alloc was performed using the procedure described in step-6E, 
with nBu3SnH as hydride donor. 
Step-6H. Cleavage from the resin and purification. A solution of TFA in CH2Cl2 (0.6% v/v, 
20 ml) was added to the resin with agitation for 5 min at room temperature. The resin was 
then filtered, and the cleavage procedure was repeated four more times. The resin was then 
washed with methanol, and finally all organic filtrates were combined and evaporated to 
dryness in vacuo. The hexapeptide 1-OH (26 mg, >95% purity) was then obtained by 
preparative reverse-phase HPLC using a preparative C18 column and a gradient of 5-35% 
MeCN in H2O + 0.1% TFA. ES-MS found m/z 900.5 ([M+H]+). 1H-NMR (600 MHz, DMSO, 
300 K) chemical shift assignments were obtained from 1D and 2D 1H-NMR spectra and are 
given in Table-I. 
 
Table-I. 
 
2. Peptide thioesters 
The synthesis of the hexapeptide S-phenyl thioester 1-SPh, hexapeptide-SCoA thioester 
1-SCoA, as well as the hexapeptide-PCP conjugate 1-S-PCP was achieved using methods 
described previously (Vitali et al., 2003; Woithe et al., 2007; Zerbe et al., 2004). 
 
Synthesis of hexapeptide S-phenyl thioester (1-SPh) 
The hexapeptide 1-OH (2 mg) in freshly distilled DMF (1 ml) was stirred with PyBOP 
(1.2 eq), DIEA (1.2 eq) and thiophenol (2.4 eq) under nitrogen atmosphere. The reaction was 
monitored by LC/MS and was complete after 10 min. After lyophilisation, the resulting 
hexapeptide S-phenyl thioester (1-SPh) was purified by semi-preparative reverse-phase 
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HPLC (C18 Vydac 218TP1010, 250/10, pore diameter 300Å, particle size 5 µm) with a 
gradient of 5-100% MeCN+0.1% TFA in water+0.1% TFA in 5 column volumes at a flow 
rate of 5 ml/min. The corresponding peptide S-phenyl thioester was obtained in ≈90% yield. 
ES-MS m/z = 992.4 ([M+H]+). Chemical shift assignments were obtained from 1D and 2D 
1H-NMR spectra and are given in Table-II. 
 
Table-II. 
 
Synthesis of hexapeptide-SCoA thioester (1-SCoA) 
The peptide S-phenyl thioester 1-SPh (2 mg) and coenzyme A (4 eq) were stirred in 
sodium phosphate buffer (4 ml, 50 mM, pH 8.5). The reaction was complete after 120 min, as 
monitored by LC/MS and the product was purified by semi-preparative HPLC on a reverse 
phase C18 column (Vydac 218TP1010, 250/10, pore diameter 300Å, particle size 5 µm) using 
a gradient of 45-100% MeCN in 20 mM NH4AcO in 5 column volumes, with a flow rate of 
5 ml/min and subsequent desalting using a gradient of 25-40% MeCN+0.1% TFA in 
water+0.1% TFA in 5 column volumes at 5 ml/min. The corresponding hexapeptide-SCoA 
thioester 1-SCoA was recovered in 40-60% yield. MALDI-MS m/z 1649.0±0.5 ([M+H]+). 
Chemical shift assignments were obtained from 1D and 2D 1H-NMR spectra and are given in 
Table-III. 
 
Table-III. 
 
Synthesis of hexapeptide-PCP conjugate (1-S-PCP) 
The reaction mixture containing the following components at the concentrations given [apo-
PCP (120 µM), hexapeptidyl-CoA thioester 1-SCoA (100 µM), B. subtilis Sfp (5 µM) and 
MgCl2 (50 mM) in Tris/HCl buffer (50 mM, pH 7.5)], weres incubated at 37°C for 30 min. 
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The reaction was monitored by analytical HPLC (Vydac C18 218TP54 column, 250x4.6mm, 
pore diameter 300Å, particle size 5 µm) using a gradient of 5-100% MeCN+0.1% TFA in 
water+0.1% TFA over 4 column volumes at 1 ml/min. The conversion proceeded 
quantitatively. The resulting peptide-PCP conjugate 1-S-PCP was isolated by HPLC 
chromatography and the identity of the peptide-PCP conjugate was confirmed by MALDI-
MS (1-S-PCP: m/z 11579±2 [M+H]+, calc. mass: 11579). 
Upon complete reaction, the mixture was dialysed against HEPES buffer (25 mM, 
pH 7.0, 50 mM NaCl), and the resulting solution containing the peptide-PCP conjugate 1-S-
PCP was used in assays without further purification. 
 
3.  In Vitro Assays with OxyB 
Assays with OxyB were carried out essentially as described earlier (Woithe et al., 2007; 
Zerbe et al., 2004). The assay contained the following components at the concentrations 
given: peptide-PCP-conjugate 1-S-PCP (80 µM), OxyB (8 µM), recombinant spinach 
ferredoxin (20 µM), E. coli flavodoxin reductase (10 µM), NADPH (1 mM), glucose-6-
phosphate (1 mM), glucose-6-phosphate-dehydrogenase (0.5 U) in HEPES buffer (25 mM, 
pH 7.0, 50 mM NaCl). Incubation at 30°C for 60 min was followed by addition of 1/10 
volume of a 25 % v/v aqueous hydrazine solution. Further incubation at 30°C for 30 minutes 
yielded the peptide hydrazides, which were separated from proteins by solid phase extraction. 
The peptidic fraction was analyzed by analytical HPLC (see Figure-6) on a reverse-phase 
C18 Zorbax Eclipse XDB column eluting with a gradient of 5-40% acetonitrile+0.1% TFA in 
water+0.1% TFA in 8 column volumes with a flow rate of 1 ml/min.   
 The major product isolated from the assay (Figure-6) was the monocyclic peptide 
hydrazide (12-NHNH2), as confirmed by high-resolution MS (exact mass calcd. for 
C45H53N9O12Na: 934.3711 ([M+Na]+), m/z found 934.3709), ESI-MS/MS and 1D and 2D 
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COSY, TOCSY and NOESY spectra. 1H-NMR chemical shift assignments are given in 
Table-IV. The occurrence of epimeric products during peptide S-PCP-thioester formation 
and/or the OxyB assay and work-up has been documented in earlier studies (Geib et al., 
2008; Woithe et al., 2008). 
 
Figure-6. 
        
Table-IV. 
 
4.  Production and purification of enzymes 
Production and purification of OxyB 
Recombinant His6-tagged OxyB was produced and purified as described earlier (Zerbe et 
al., 2002). Thus, recombinant His6-tagged OxyB was produced in E. coli BL21(DE3)pLysS, 
transformed with a plasmid (pOCI1047) containing the oxyB gene. TB medium (400 ml) with 
ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml) was inoculated with a preculture and 
incubated at 24°C with shaking at 200 rpm. δ-Aminolevulinic acid (8 mg) was added at 
A600 = 0.5. Cultures were induced with IPTG at A600 = 1 and shaken at 22°C. At 20 h post-
induction a second portion of δ-aminolevulinic acid (8 mg) was added and the cultures were 
harvested by centrifugation after another 24 h. 
The cells were disrupted in phosphate buffer (50 mM potassium phosphate, pH 7.4, 10% 
glycerol, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% β-mercaptoethanol) by 
sonication. The E. coli cell-free extract containing His6-OxyB was applied to a Ni-NTA 
column (0.5 cm x 5 cm, Ni2+ NTA superflow, Qiagen) pre-equilibrated with buffer A 
(potassium phosphate, pH 7.4, 50 mM, with KCl (300 mM), and imidazole (20 mM)), at a 
flow rate of 2 ml/min. After washing (20 column volumes of buffer A) the His6-tagged 
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protein was eluted in buffer A with 300 mM imidazole, and dialysed against buffer B (Tris-
HCl (50 mM), pH 7.5, and EDTA (0.5 mM)). The protein was then chromatographed on 
MonoQ (HR10/10, GE Healthcare) in buffer B at a flow rate of 2 ml/min, and eluted with a 
linear gradient of 0 – 0.4 M KCl over 100 ml with a flow rate of 1.5 ml/min. His6-OxyB 
eluted with 0.17 M KCl, and showed a single band by SDS-PAGE, gave an electrospray mass 
spectrum consistent with the expected mass, and the correct N-terminal sequence by Edman 
degradation. The concentration of the purified P450 was determined spectrophotometrically 
from CO difference UV spectra using dithionite-reduced heme and an extinction coefficient 
of 91 mM-1 cm-1 (Omura and Sato, 1964). 
The amino acid sequence of the His6-tagged OxyB (His-tag underlined) is shown below. 
1   GSSHHHHHHS SGLVPRGSHM SEDDPRPLHI RRQGLDPADE LLAAGALTRV  
51  TIGSGADAET HWMATAHAVV RQVMGDHQQF STRRRWDPRD EIGGKGIFRP  
101 RELVGNLMDY DPPEHTRLRR KLTPGFTLRK MQRMAPYIEQ IVNDRLDEME  
151 RAGSPADLIA FVADKVPGAV LCELVGVPRD DRDMFMKLCH GHLDASLSQK  
201 RRAALGDKFS RYLLAMIARE RKEPGEGMIG AVVAEYGDDA TDEELRGFCV  
251 QVMLAGDDNI SGMIGLGVLA MLRHPEQIDA FRGDEQSAQR AVDELIRYLT  
301 VPYSPTPRIA REDLTLAGQE IKKGDSVICS LPAANRDPAL APDVDRLDVT  
351 REPIPHVAFG HGVHHCLGAA LARLELRTVF TELWRRFPAL RLADPAQDTE  
401 FRLTTPAYGL TELMVAW* 
 
 
Production and purification of spinach ferredoxin 
Recombinant His6-tagged spinach ferredoxin was produced and purified as described 
earlier (Woithe et al., 2007). Thus, a plasmid containing the His6-tagged ferredoxin gene 
(pOCI829) was introduced into E. coli BL21(DE3)pLysS (Novagen). The spinach ferredoxin 
was produced in LB medium containing ampicillin (100 µg/ml), chloramphenicol (34 µg/ml) 
and FeSO4 (10 µM) at 37°C. The cultures were induced at A600 = 1.4 with IPTG (0.1 mM) 
and further cultivated at 30°C for 4 hours. Cell pellets were resuspended in phosphate buffer 
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(20 ml, 50 mM, pH 7.4, 300 mM KCl, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% 
2-mercaptoethanol, 10% glycerol) and disrupted by sonication. After centrifugation (40'000 × 
g for 45 min), the supernatant was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) 
and equlibrated with 20 ml buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 20 mM 
imidazole). After washing with 40 ml buffer A, recombinant spinach ferredoxin was eluted 
with 10 ml buffer A containing 300 mM imidazole. Fractions containing the red spinach 
ferredoxin were dialysed against 50 mM Tris-HCl buffer pH 7.5, 10% glycerol, flash-frozen 
and stored at -80°C. 
The molecular weight of the recombinant spinach ferredoxin was analyzed by ES-MS 
(pH 9 (+ [2Fe-2S] cluster) m/z obs. 12818 ±1 [M+H+], calc. 12818; pH 3 (with loss of the 
[2Fe-2S] cluster) m/z obs. 12645 ±1 [M+H+], calc. 12646). The UV spectrum in Tris-HCl 
buffer (50 mM, pH 7.5) showed absorption maxima (λmax) at 273, 328, 420 and 465 nm, in 
agreement with the literature values for plant [2Fe-2S] ferredoxins (Armengaud et al., 2000; 
Crispin et al., 2001; Tagawa and Arnon, 1962). The solution concentration was determined by 
UV using ε422nm = 9700 cm-1M-1 (Crispin et al., 2001). 
The amino acid sequence of the His6-spinach ferredoxin is shown below, with the His-tag 
underlined: 
1 GSSHHHHHHS SGLVPRGSHM AAYKVTLVTP TGNVEFQCPD DVYILDAAEE  
51 EGIDLPYSCR AGSCSSCAGK LKTGSLNQDD QSFLDDDQID EGWVLTCAAY  
101 PVSDVTIETH KEEELTA 
 
Production and purification of PCP domain 
A recombinant His6-tagged PCP domain from module-7 of the vancomycin NRPS (vpsC) 
from A. orientalis (residues 967-1043, including a Cys979Ser mutation, to avoid dimer 
formation through oxidation) was produced and purified as described earlier (Woithe et al., 
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2007). Plasmid pOCI865 was introduced into E. coli Rosetta2(DE3)pLysS (Novagen). An 
overnight pre-culture (20 ml) was used to inoculate TB medium (400 ml) containing 
ampicillin (100 µg/ml) and chloramphenicol (34 µg/ml), with incubation at 37°C and shaking 
at 200 rpm. The cultures were induced at A600 = 1.2 with IPTG (0.1 mM) and further 
cultivated at 22°C for 6 hours. Cell pellets were resuspended in 20 ml phosphate buffer 
(50 mM, pH 7.4, 1 mM DTT, 1 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol, 
10% glycerol) and disrupted by sonication (three bursts of 60 s). After centrifugation (40'000 
× g for 45 min), the supernatant was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) 
and equilibrated with 20 ml buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 
20 mM imidazole). After washing with 40 ml buffer A, recombinant PCP was eluted with 
10 ml buffer A containing 300 mM imidazole. Eluted protein fractions were purified further 
by anion exchange chromatography (MonoQ HR10/10, GE Healthcare) in buffer B 
(20 mM diethanolamine pH 8.5, gradient: 0-0.5 M KCl in 15 cv). The proteins eluted at 
0.28 M KCl. The isolated PCP was dialysed against 50 mM Tris-HCl buffer pH 7.5, 10% 
glycerol, flash-frozen and stored at -80°C. 
The concentration of purified PCP was measured spectrophotometrically at 562 nm 
using a colorimetric BCA protein assay (Pierce, extinction coefficient ε562nm = 
6833 cm-1M-1 determined by quantitative amino acid analysis). The purified protein 
showed a single band by SDS-PAGE and gave an electrospray mass spectrum (ESI-MS) 
corresponding to the loss of N-terminal methionine (m/z obs. [M+H]+ 10360±2, calc. 10358). 
The sequence of the PCP, which includes residues 967–1043 of VpsC and a His6-tag 
(underlined) and a Cys-to-Ser mutation (underlined), is shown below. 
1    GSSHHHHHHS SGLVPRGSHM EKAPENETEK VLSALFAEIL SVDQVGVDDA  
51   FQDLGGSSAL AMRLVARIRE ELGEDLPIRQ LFSSPTPAGL ARALAAK 
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Production and purification of E. coli NADPH-flavodoxin reductase 
The production and purification of His6-tagged E. coli NADPH-flavodoxin reductase (eco-
FlvR) was performed as described previously (Woithe et al., 2007). The plasmid pOCI819 
containing the required gene was introduced into E. coli BL21(DE3)pLysS cells (Novagen). 
His6-tagged eco-FlvR was produced in LB medium containing ampicillin (100 µg/ml) and 
chloramphenicol (34 µg/ml) at 37°C. The cultures were induced at A600 = 0.6 with IPTG 
(0.1 mM) and further cultivated at 37°C for 4 hours. 
The cell pellet was resuspended in 20 ml phosphate buffer (50 mM, pH 7.4, 1 mM DTT, 
1 mM PMSF, 1 mM benzamidine, 0.1% 2-mercaptoethanol, 10% glycerol) and disrupted by 
sonication (three bursts of 60 s). After centrifugation (40'000 × g for 45 min) the supernatant 
was loaded onto a 7 ml Ni-NTA superflow column (Qiagen) and equilibrated with 20 ml 
buffer A (50 mM phosphate buffer pH 7.4, 300 mM KCl, 20 mM imidazole). After washing 
with 40 ml buffer A, the recombinant eco-FlvR was eluted from the column with 10 ml buffer 
A containing 300 mM imidazole. Fractions containing bright yellow eco-FlvR were dialysed 
against 50 mM Tris-HCl buffer pH 7.5, 10% glycerol, flash-frozen and stored at -80°C.  
The UV-Vis absorbance spectrum of the protein showed the typical maxima at 400, 
456 nm and 483 nm (Jenkins and Waterman, 1994). The flavodoxin reductase concentration 
was determined using the absorbance of bound FAD at 456 nm (ε = 7100 M-1 cm-1) (Fujii and 
Huennekens, 1974). The purified protein showed a single band by SDS-PAGE and gave an 
ES-MS corresponding to the loss of N-terminal methionine (m/z obs. [M+H]+ 29776±6, calc. 
29783). 
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Figure legends 
 
Figure-1. Structures of vancomycin and teicoplanin. 
 
 
 
Figure-2. The NRPS assembly line for the biosynthesis of vancomycin-like antibiotics 
deduced by bioinformatic analyses. The domain structures of modules-1 to -7 are shown. 
Peptide intermediates likely to be bound to PCPs at various stages of assembly are also 
shown. 
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Figure-3. Synthetic approach to peptide-PCP thioester substrates. 
 
 
Figure-4. The model hexapeptide 1 and protected amino acids required for its synthesis. 
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Figure-5. Synthetic route to amino acid 2. 
 
 
Figure-6. The reaction catalyzed by OxyB using 1-S-PCP as substrate. Shown bottom left is 
a section of an HPLC chromatogram of the product mixture. By ES-MS peaks 1 and 2 
correspond to epimeric linear peptide hydrazides, whereas peaks 3 and 4 correspond to 
epimeric monocyclic peptide hydrazides. Bottom right shows the fragment ions observed for 
peak-4 upon ES-MS/MS analysis. 
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Table-I. 1H-NMR Chemical shift assignments for peptide 1-OH (500 MHz at 300 K in 
DMSO-d6). 
 
Residue NH C(α)-H C(β)-H Others 
Leu1 8.64 3.58 1.51, 1.38 C(γ)H=1.49, C(δ)H3=0.79, 0.84, NMe=1.94 
Tyr2 8.82 4.76 2.95, 2.56 C(δ)H=7.04, C(ε)H=6.62, OH=9.32 
Asn3 8.45 4.67 2.45, 2.31 N(δ)H=7.30, 6.93 
Hpg4 8.06 5.51 - C(γ)H=7.16, C(δ)H=6.66, OH=9.32 
Hpg5 8.72 5.54 - C(γ)H=7.01, C(δ)H=6.62, OH=9.18 
Bht6 8.10 4.26 4.94, 
OH=5.51 
C(δ)H=6.91, C(ε)H=6.51, OH=9.20 
 
 
 
 
Table-II. 1H-NMR Chemical shift assignments for peptide 1-SPh (500 MHz at 300 K in 
DMSO-d6). 
 
Residue NH C(α)-H C(β)-H Others 
Leu1 - 3.56 1.50, 1.37 C(γ)H=1.50, C(δ)H3=0.77, 0.83, NMe=1.96 
Tyr2 8.78 4.77 2.96, 2.57 C(δ)H=7.04, C(ε)H=6.63, OH=9.15 
Asn3 8.44 4.68 2.47, 2.32 N(δ)H=7.28, 6.91 
Hpg4 8.03 5.58 - C(γ)H=7.18, C(δ)H=6.58, OH=9.25 
Hpg5 8.85 5.78 - C(γ)H=7.02, C(δ)H=6.64, OH=9.32 
Bht6 8.80 4.47 5.05, 
OH=5.74 
C(δ)H=7.02, C(ε)H=6.57, OH=9.26 
COSPh - - - 7.46, 7.26 
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Table-III. 1H-NMR Chemical shift assignments for peptide 1-SCoA (600 MHz at 300 K in 
DMSO-d6). 
 
Residue NH C(α)-H C(β)-H Othersa 
Leu1 - 3.58 1.50, 1.47 C(γ)H=1.47, C(δ)H3=0.75, 0.83, NMe=1.98 
Tyr2 8.84 4.74 2.94, 2.58 C(δ)H=7.04, C(ε)H=6.633 
Asn3 8.49 4.64 2.48, 2.32 N(δ)H=7.31, 6.91 
Hpg4 8.01 5.50 - C(γ)H=7.16, C(δ)H=6.66 
Hpg5 8.74 5.71 - C(γ)H=7.00, C(δ)H=6.63 
Bht6 8.60 4.34 5.03 C(δ)H=6.98, C(ε)H=6.54 
COSCoA - - - 1=2.75, 2.85, 2=3.09, 3=8.19, 4=2.29, 
5=3.30, 6=7.78, 7=3.43, 8=0.74, 9=0.96, 
10=3.80, 11=4.10, 12=4.35, 13=4.89, 
14=4.72, 15=5.94, 16=8.42, 17=8.17 
 
a The numbering used for assignments in the CoA are shown below: 
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Table-IV. 1H-NMR Chemical shift assignments for peptide 12-NHNH2 (600 MHz at 310 K 
in DMSO-d6). 
 
Residue NH C(α)-H C(β)-H Others 
Leu1 8.62 3.58 1.47, 1.37 C(γ)H=1.47, C(δ)H3=0.74, 0.80, NMe=1.96 
Tyr2 8.77 4.77 2.97, 2.59 C(δ)H=7.04, C(ε)H=6.62, OH=9.12 
Asn3 8.47 4.73 2.57, 2.38 N(δ)H=7.30, 6.91 
Hpg4 7.94 5.36 - C(γ1)H=6.23, C(γ2)H=6.64, C(δ)H=6.78, 
OH=9.32 
Hpg5 8.71 5.27 - C(γ)H=7.19, C(δ)H=6.72, OH=9.40 
Bht6 8.65 4.67 5.30 C(δ1)H=6.94, C(δ2)H=7.56, C(ε1)H=7.24, 
C(ε2)H=7.12 
CONHNH2 - - - 7.15, 7.06, 6.98 
 
 
 
 
 
 
 
 
 
